PlumX Metrics
Embed PlumX Metrics

Monitoring of multiple sclerosis immunotherapy : fffrom single candidates to biomarker networks

Journal of Neurology, ISSN: 0340-5354, Vol: 255, Issue: SUPPL. 6, Page: 48-57
2008
  • 23
    Citations
  • 0
    Usage
  • 43
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Applying microarray technology to identify new diagnostic and prognostic markers in peripheral blood cells (PBC) after therapeutic intervention opens great perspectives regarding patient subclassification. Three recombinant products of the pleiotropic agent interferon beta (rIFN-β) are available for disease modifying therapy of relapsing remitting multiple sclerosis (RRMS), a complex inflammatory autoimmune disease that targets the central nervous system. They differ according to formulation, route of administration and dosage regimens. The currently, only partially understood mechanism of action of injected rIFN-β into human organisms needs provision with accessory key molecules; in addition, the significance of established clinical IFN-β response criteria that distinguish responding from non-responding patients remain unclear. With respect to these major questions, we discuss promising candidates on the gene transcription level, attained from scientific MS literature that included a longitudinal aspect. Reviewed studies were in part carried out with distinct gene interrogating platforms (GeneArrays; RT-PCR), settings (in vitro; ex vivo), and study designs (drug formulations and regimen; inclusion criteria and clinical endpoints), hampering meaningful meta-analysis. Nevertheless, PBC from therapy-naïve MS patients, rIFN-β treated MS patients, and healthy controls served to characterize facets of both the disease and its treatment. Hence, the field of MS transcriptomics in immunomodulatory therapy is (by far) not adequately understood and should be embedded into systems biology disciplines, yielding multi-layer analyses that deliver timely identification of MS subjects who will profit from applied rIFN-β therapy. © 2008 Steinkopff-Verlag.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know